

Epidermale Nekrolyse als lebensbedrohliche Erkrankung

Ein Fall für das Schwerbrandverletzententrum

TANJA KHEIRI, THOMAS PIERSON, HENRIK MENKE
OFFENBACH

1. Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. *Br J Dermatol* 68: 355–361
2. Stevens AM, Johnson FC (1922) A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. *Am J Dis Child* 24: 526–533
3. Bastuji-Garin S, Rzany B, Stern RS, et al (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. *Arch Dermatol* 129: 92–96
4. Halevy S, Ghislain PD, Mockenhaupt M, et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. *J Am Acad Dermatol* 58: 25–32
5. Rzany B, Mockenhaupt M, Baur S, et al (1996) Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990–1992). Structure and results of a population-based registry. *J Clin Epidemiol* 49: 769–773
6. Mockenhaupt M (2016) Das Dokumentationszentrum schwerer Hautreaktionen (dZh). In: Lehnhardt M, et al (Hrsg) *Verbrennungschirurgie*. Springer, Berlin, Kap 37, S 403–416
7. Paulmann M, Mockenhaupt M (2015) Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnose, Ätiologie und Therapie. *J Dtsch Dermatol Ges* 13: 625–645
8. Salopek TG (1997) Nikolsky's sign: is it 'dry' or is it 'wet'? *Br J Dermatol* 136: 762–767
9. Duong TA, de Prost N, Ingen-Housz-Oro S, et al (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. *Br J Dermatol* 172: 400–405
10. Jäckel R, Fuchs M, Raff T, Wiedemann B (2002) Arzneimittelbedingte toxisch epidermale Nekrolyse mit Beteiligung des Intestinal- und Respirationstraktes. *Anaesthesist* 51: 815–819
11. Wang L, Mei XL (2017) Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 88 Chinese patients. *Chin Med J* 130: 1062–1068
12. Cote B, Wechsler J, Bastuji-Garin S, et al (1995) Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. *Arch Dermatol* 131: 1268–1272
13. Bastuji-Garin S, Fouchard N, Bertocchi M, et al (2000) SCOR-TEN: a severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol* 115: 149–153
14. Garcia-Doval I, LeCleach L, Bocquet H, et al (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? *Arch Dermatol* 136: 323–411
15. Sotozono C, Ang LP, Koizumi N, et al (2007) New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. *Ophthalmology* 114: 1294–1302
16. McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. *Plast Reconstr Surg* 102: 1018–1022
17. Palmieri TL, Greenhalgh DG, Saffle JR, et al (2002) A multi-center review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. *J Burn Care Rehabil* 23: 87–96
18. Creamer D, Walsh SA, Dziewulski P, et al (2016) U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *Br J Dermatol* 174: 1194–1227
19. Kardaun SH, Jonkman MF (2007) Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. *Acta Derm Venereol* 87: 144–148
20. McCullough M, Burg M, Lin E, et al (2017) Stevens-Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience. *Burns* 43: 200–205
21. Trent JT, Kirsner RS, Romanelli P, et al (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. *Arch Dermatol* 139: 39–43
22. Barron SJ, Del Vecchio MT, Aronoff SC (2015) Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. *Int J Dermatol* 54: 108–115
23. Trent JT, Fangchao M, Kerdel F, et al (2007) Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. *Exp Rev Dermatol* 2: 299–303
24. Huang YC, Chien YN, Chen YT, et al (2016) Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. *G Ital Dermatol Venereol* 151: 515–524
25. Paquet P, Pierard GE, Quatresooz P (2005) Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). *Int Arch Allergy Appl Immunol* 136: 205–216